The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.

The present invention relates to synthetic α-secretase (SAS) and a use thereof. According to the present invention, a synthetic α-secretase, which is a fusion protein comprising, as an active ingredient, NIa protease, a fragment thereof or a variant thereof, can inhibit the formation of amyloid β, degrade extracellularly secreted amyloid β, and degrade amyloid β internalized in cells. Therefore, the present invention allows intracellular/extracellular degradation of amyloid β, which is the cause of various diseases including Alzheimer's disease, and thus can be usable in the prevention or treatment of such diseases.

In order to provide a membrane protein production method which does not require the step of solubilizing a membrane protein and which allows the membrane protein having an excellent quality to be obtained with a high yield, a method in accordance with an embodiment of the present invention includes: a step (a) of preparing a reaction solution for cell-free protein synthesis, the reaction solution containing (i) a template nucleic acid which encodes the membrane protein, (ii) a lipid, and (iii) a detergent which is contained at a concentration equal to or higher than a critical micelle concentration; and a step (b) of synthesizing the membrane protein while the concentration of the detergent in the reaction solution is maintained at a concentration equal to or higher than a critical micelle concentration.

The disclosure relates to nucleic acid expression cassettes and vectors for the treatment of neurodegenerative disorders. Methods of treating neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, Lewy body dementia, memory loss, cognitive impairment, and mild cognitive impairment are also provided.

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.

Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.

Described herein are methods of identifying a mammal having a neurological disease or disorder, such as AD or MCI, or at risk for developing a neurological disease or disorder, such as AD or MCI. Provided herein are also methods of monitoring the progression of a neurological disease or disorder in a patient or monitoring the effectiveness of therapeutic agent or treatment of a patient having a neurological disease or disorder.

The present disclosure discloses preparation and use of sugar-targeting nanoparticles for modifying siRNA. A sugar-targeting nanoparticle, including targeting nanocarriers, wherein the targeting nanocarriers are formed by linking in sequence a targeting molecule, a first linking compound, a first hydrophilic biomaterial, a second linking compound and a cationic compound through chemical bonds; the first linking compound and the second linking compound both have a carboxyl group; the first linking compound has a maleimido group at the same time, and the targeting molecule is a cycloaldohexose. Providing the cycloaldohexose as the targeting molecule facilitates the nanoparticles targeting the GLUT-1 protein on the capillary endothelial cell membrane on the blood brain barrier, and the nanoparticles are transferred to the brain with high efficiency through the effect of the GLUT-1 protein to transport cycloaldohexose, thereby effectively penetrating the blood brain barrier, and helping to improve the efficiency of sugar-targeting nanoparticles penetrating the BBB.

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders